Highly Galactosylated Anti-PD-L1 (Atezolizumab) Antibody (CAT#: BioBet-GA-044ZP) Datasheet

CD274

CD274 molecule

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and nonhematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin Vlike and Clike domains. Interaction of this ligand with its receptor inhibits Tcell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic Tcell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

B7-H, B7H1, PDL1, PD-L1, PDCD1L1, PDCD1LG1

Plasma membrane, Endosome

Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.

1.It plays a key role in inducing and maintaining immune tolerance to oneself (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, it regulates the activation threshold of t cells and limits the effector response of t cells (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10) (PubMed: 10581077). 2. Tumors use the pdcd1 mediated inhibitory pathway to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).

1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. 2.Glycosylation at Asn35, Asn192, Asn200, and Asn219 3.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Atezolizumab

Humanized

Human

Atezolizumab is a humanized monoclonal antibody that specifically targets cell death ligand 1 (PD-L1) programmed for proteins expressed on the surface of tumors. Atezolizumab was used to prevent the interaction of PD-L1 and PD-1 and eliminate the inhibitory effect on the immune response seen in some cancers.

Lung Cancer Small Cell Lung Cancer (SCLC)
Metastatic Non-Small Cell Lung Cancer
Triple Negative Breast Cancer (TNBC)
Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma

MPDL3280A

Atezolizumab is a humanized IgG antibody that binds PD-L1 and prevents the interaction of programmed cell death protein 1 (PD-1) and B7-1. PD-L1 can be highly expressed on certain tumors, especially bladder cancer, which is thought to lead to reduced activation of immune cells (especially cytotoxic T cells). Preventing the interaction of PD-L1 and PD-1 can eliminate the inhibitory effect on immune response (such as anti-tumor immune response), thereby triggering anti-tumor response.

Lung Cancer Small Cell Lung Cancer (SCLC)
Metastatic Non-Small Cell Lung Cancer
Triple Negative Breast Cancer (TNBC)
Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma